Stomach Cancer clinical trials

Explore recruiting stomach cancer clinical trials.

Recruiting stomach cancer studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Stomach Cancer trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Perioperative Treatment in Resectable Gastric Cancer with Spartalizumab (PDR001) in Combination with fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT): A phase II study (GASPAR)

France

Therapeutic exploratory (Phase II) EU CTIS Study details

Treatment of peritoneal dissemination in stomach cancer patients with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy; PERISCOPE-2

Sweden, Finland, Denmark, Netherlands

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 3, Multicenter, Open-label, Randomized Study to Compare the Efficacy and Safety of MK-2870 Versus Treatment of Physician’s Choice in 3L+ Advanced/Metastatic Gastroesophageal Adenocarcinoma (Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, and Esophageal Adenocarcinoma)

Belgium, Germany, Italy, Spain, Poland, Denmark +1 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Randomized, Multi-center, Double-blind, Placebo-controlled Phase 3 Study of Bemarituzumab plus Chemotherapy versus Placebo plus Chemotherapy in Subjects with Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer with FGFR2b Overexpression FORTITUDE-101)

Poland, Hungary, Latvia, Denmark, Estonia, France +12 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

PRODIGE 111 – DOMZIGAST A randomized phase II study evaluating FOLFIRI vs FOLFIRI plus Domvanalimab (anti-TIGIT) and Zimberelimab (anti-PD1) in patients with advanced gastric or gastro-oesophageal junction adenocarcinoma with progression during or after peri-operative chemotherapy.

France

Therapeutic exploratory (Phase II) EU CTIS Study details

INTERACT stomach

Netherlands

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

Stomach Cancer trials by city

Stomach Cancer in Toronto Stomach Cancer in Vancouver Stomach Cancer in Montreal Stomach Cancer in Calgary Stomach Cancer in Edmonton Stomach Cancer in Ottawa Stomach Cancer in Winnipeg Stomach Cancer in Quebec City Stomach Cancer in Hamilton Stomach Cancer in Kitchener Stomach Cancer in London Stomach Cancer in Halifax Stomach Cancer in New York Stomach Cancer in Los Angeles Stomach Cancer in Chicago Stomach Cancer in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease